EC Number |
Substrates |
Organism |
Products |
Reversibility |
---|
4.6.1.17 | (8S)-3',8-cyclo-7,8-dihydroguanosine 5'-triphosphate |
- |
Escherichia coli |
cyclic pyranopterin phosphate + diphosphate |
- |
? |
4.6.1.17 | (8S)-3',8-cyclo-7,8-dihydroguanosine-P[CH2]PP |
- |
Escherichia coli |
cyclic pyranopterin phosphate + diphosphate |
- |
? |
4.6.1.17 | GTP |
- |
Mycobacterium tuberculosis |
cyclic pyranopterin phosphate + diphosphate |
- |
? |
4.6.1.17 | GTP |
- |
Mycobacterium tuberculosis H37Rv |
cyclic pyranopterin phosphate + diphosphate |
- |
? |
4.6.1.17 | more |
the formation of the cyclic pyranopterin monophosphate from GTP is catalyzed by MaoA and requires the action of MoaC |
Thermus thermophilus |
? |
- |
? |
4.6.1.17 | more |
the formation of the cyclic pyranopterin monophosphate from GTP is catalyzed by MaoA and requires the action of MoaC |
Sulfurisphaera tokodaii |
? |
- |
? |
4.6.1.17 | more |
the GTP molecule first binds to MoaA and an intermediate formamidopyrimidine-type compound is generated which is subsequently used by MoaC. MoaC catalyzes the release of diphosphate from the formamidopyrimidine-type compound and the formation of the cyclic phosphate of precursor Z, which is formed either via the formation of intermediate compound E (formamido-type) or PBM (pteridinebenzomonophosphate) |
Mycobacterium tuberculosis |
? |
- |
? |
4.6.1.17 | more |
molecular docking studies with probable ligands suggests that pteridinebenzomonophosphate is the most likely ligand. Molybdenum cofactor biosynthesis protein A1, MoaA1, and MoaC2 interact with each other in a complex and do not act independently of each other, homology modeling of MoaA1 complexed with MoaC2 and protein-protein interaction analysis, detailed docking study, overview |
Mycobacterium tuberculosis |
? |
- |
? |
4.6.1.17 | more |
the formation of the cyclic pyranopterin monophosphate from GTP is catalyzed by MaoA and requires the action of MoaC |
Sulfurisphaera tokodaii 7 |
? |
- |
? |
4.6.1.17 | more |
the GTP molecule first binds to MoaA and an intermediate formamidopyrimidine-type compound is generated which is subsequently used by MoaC. MoaC catalyzes the release of diphosphate from the formamidopyrimidine-type compound and the formation of the cyclic phosphate of precursor Z, which is formed either via the formation of intermediate compound E (formamido-type) or PBM (pteridinebenzomonophosphate) |
Mycobacterium tuberculosis H37Rv |
? |
- |
? |